查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984159

细胞和基因治疗药物输送装置市场：按产品类型、装置类型、治疗方法、分销管道和最终用户划分－2026-2032年全球市场预测

Cell & Gene Therapy Drug Delivery Devices Market by Product Type, Device Type, Therapy Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于细胞和基因治疗的药物输送装置的市值将达到 33.9 亿美元，到 2026 年将增长到 44.8 亿美元，到 2032 年将达到 267.9 亿美元，复合年增长率为 34.33%。

主要市场统计数据
基准年 2025 33.9亿美元
预计年份：2026年 44.8亿美元
预测年份 2032 267.9亿美元
复合年增长率 (%) 34.33%

前瞻性的介绍概述了影响先进生物製药输送装置策略的技术、临床和监管挑战。

先进生物製药与精准给药装置的融合正在重塑临床医生和医疗保健系统应对复杂治疗方法的方式。装置工程、材料科学和互联技术的最新创新为提高细胞和基因疗法的给药准确性、患者依从性和安全性创造了新的机会。同时，涉及活细胞和基因载体的临床项目对装置的适用性、低温运输物流和无菌给药提出了严格的要求，这需要对产品设计和操作流程进行新的评估。

对正在重新定义药物输送的器材技术、分散式医疗和监管融合的关键趋势进行全面分析。

细胞和基因治疗输送装置的格局正在经历一场变革，其驱动力来自治疗复杂性的提升、以患者为中心的护理模式的兴起以及与数位医疗的融合。治疗方法研发人员越来越重视微创和门诊给药，促使医疗设备製造商不断创新，研发出自动化注射器、无针注射器、微流体系统和穿戴式输注平台等产品，以减少病患对诊所的依赖。同时，分散式医疗的趋势也加速了对便于居家使用的医疗设备的投资，这些器材既能满足患者对生物製药的储存管理和环境控制需求，又能确保其操作便捷。

对 2025 年前的累积关税措施如何重塑行政管理系统的采购、供应商选择和製造的韧性进行策略评估。

针对进口医疗组件和成品医疗设备的新关税措施的出台，给支持细胞和基因治疗输送系统的供应链带来了巨大压力。这些将于2025年前逐步实施的累积关税措施，将推高自动注射器、输液帮浦和一次性耗材中使用的某些上游原料、特殊聚合物和精密组件的成本。因此，采购团队正在重新审视其供应商组合，探索替代货源，并重新评估其总到岸成本模型，以维持专案的可行性和价格透明度。

深入了解将医疗设备类型、最终用户、产品形式、治疗方法和通路与策略性产品决策连结起来的详细细分市场。

将产品开发和商业化策略与临床和营运实际情况相结合，需要对细分市场动态有深刻的理解。就设备类型而言，竞争格局涵盖自动注射器、植入式帮浦、输液帮浦、微流体装置、无针注射器、预填充式注射器和传统注射器，每种装置在精确给药、便携性和监管复杂性之间都存在独特的权衡取舍。同样，终端用户分析也凸显了诊所、居家医疗机构、医院和专科医疗中心的不同需求。医院需要整合的设备生态系统和高通量可靠性，而居家医疗和专科医疗中心则优先考虑易用性、紧凑的外形尺寸和远端监控功能。

本研究务实地检验了区域法规环境、基础设施成熟度和医疗保健服务模式如何影响设备的部署和采用。

区域趋势对医疗器材策略、监管互动和商业化实施有显着影响，因此需要针对不同区域采取差异化的有效规划方法。在美洲，临床试验活动、集中化的高品质医疗中心以及完善的医保报销体系促进了新型给药方案的快速普及；然而，明确的医保报销路径和与支付方的积极互动对于更广泛的应用仍然至关重要。欧洲、中东和非洲（EMEA）的监管环境复杂多样，各国医疗设备框架和采购模式各不相同，因此需要製定针对特定情况的监管策略和区域价值提案。该地区某些司法管辖区也透过集中采购和与公共医疗体系的整合提供了巨大的发展机会。亚太地区是快速创新、医院基础设施不断完善以及日益重视分散式医疗模式的中心，但相关人员必须应对特定市场的监管时间表和物流挑战。

本报告深入分析了製造商、创新者和服务供应商如何协调其业务运营和伙伴关係，以加速采用基于医疗设备的治疗方法。

在输液装置领域，影响竞争优势的许多策略挑战正汇聚成企业行为的关键模式。成熟的医疗技术公司正利用其丰富的监管经验、生产规模和分销网络，拓展至专业输液系统领域，并经常寻求与治疗方法开发商建立合作关係或达成许可协议，以开发整合复合产品。同时，敏捷的Start-Ups和装置开发人员则透过模组化输液架构、紧凑型微流体处理器和配备感测器的自动注射器等平台技术进行差异化。这些技术旨在解决特定的临床难题，并能快速提升人体工学和连结性。

为医疗器材开发公司和治疗方法赞助商提供一套可操作且优先排序的策略建议，以协调创新、供应弹性和监管合规性。

行业领导者应采取整合式方法，将医疗设备创新与临床工作流程、监管策略和商业性执行相结合，以最大限度地发挥先进生物製药的治疗和营运价值。首先，应在设计过程早期就纳入人体工学和临床医生参与，以确保医疗设备满足实际应用环境（无论是在医院、专科医疗中心、诊所或家庭环境中）的实际限制。这种早期整合可以减少返工并加快监管核准。其次，对于关键零件，应建立多元化的供应链，纳入合格的二级供应商和近岸外包选项，以降低关税和前置作业时间风险，同时保持严格的品质管治。

我们高度透明的混合方法研究途径，将与专家的直接访谈与第二手资料的整合相结合，确保了严谨而实用的见解。

本研究采用混合方法，将质性专家见解与严谨的二次检验结合，以产生可操作的见解。主要资讯来源包括对医疗设备工程师、临床研究人员、药局主任和供应链高阶主管的详细访谈，以及与监管专家的结构化咨询，以了解申报和上市后要求。透过与相关人员的对话，旨在捕捉有关医疗设备易用性、病毒和非病毒载体的防护要求以及医院、诊所、专科医疗中心和居家照护机构的实际限制等方面的经验性细微差别。

简明结论总结道，医疗设备创新、营运韧性和相关人员之间的协作是决定治疗实施成功与否的关键因素。

整体结论显而易见：细胞和基因疗法的成功应用不仅需要生物製剂本身，还需要给药系统的设计和物流协调。设备技术的创新，结合数位化连接和自适应分销模式，使得复杂治疗方法的去中心化程度更高，同时也提高了对人为因素、低温运输管理以及与监管机构协调的要求。同时，关税政策的变化和区域基础设施差异等外部因素，使得积极主动的供应链策略和立足本地的商业化方法至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：细胞与基因治疗药物输送装置市场：依产品类型划分

  • 可重复使用的
  • 一次性的

第九章：细胞与基因治疗药物输送装置市场：依装置类型划分

  • 自动喷油器
  • 嵌入式泵浦
  • 点滴帮浦
  • 微流体装置
  • 无针注射器
  • 预填充式注射器
  • 注射器

第十章：细胞与基因治疗药物输送装置市场－依治疗方法划分

  • 细胞疗法
    • CAR-T疗法
    • 树突细胞疗法
    • 干细胞疗法
  • 基因治疗
    • 非病毒载体
    • 病毒载体

第十一章：细胞与基因治疗药物输送装置市场：依分销管道划分

  • 医院药房
  • 网路药房
    • 邮购药房
    • 传统网路药局
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十二章：细胞与基因治疗药物输送装置市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院
  • 专业医疗中心

第十三章：细胞与基因治疗药物传递装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：细胞与基因治疗药物输送装置市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：细胞与基因治疗药物输送装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞与基因治疗药物传递装置市场

第十七章：中国细胞与基因治疗药物输送装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • B. Braun Melsungen AG
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • Catalent, Inc.
  • Dendreon Pharmaceuticals LLC.
  • Fresenius SE & Co. KGaA
  • Gerresheimer AG
  • Helixmith Co., Ltd.
  • ICU Medical, Inc.
  • Kite Pharma, Inc. by Gilead
  • Kolon TissueGene, Inc.
  • MaxCyte, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • Terumo Corporation
  • uniQure NV
  • Vericel Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 3.39 billion in 2025 and is projected to grow to USD 4.48 billion in 2026, with a CAGR of 34.33%, reaching USD 26.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.39 billion
Estimated Year [2026] USD 4.48 billion
Forecast Year [2032] USD 26.79 billion
CAGR (%) 34.33%

A forward-looking introduction that frames the technical, clinical, and regulatory imperatives shaping delivery device strategies for advanced biologics

The convergence of advanced biologics and precision delivery devices is reshaping how clinicians and healthcare systems approach complex therapies. Recent innovations in device engineering, materials science, and connectivity have created new opportunities to improve dosing accuracy, patient adherence, and safety for cell and gene therapies. At the same time, clinical program requirements for handling living cells and genetic vectors impose exacting constraints on device compatibility, cold chain logistics, and aseptic administration, demanding a fresh evaluation of product design and operational workflows.

Stakeholders across product development, clinical operations, and commercial strategy now face a bifurcated challenge: integrate enabling delivery technologies that preserve therapeutic integrity while minimizing complexity for end users, and simultaneously navigate increasingly stringent regulatory expectations for combination product evaluation. These dynamics have elevated cross-disciplinary collaboration as a critical success factor, with engineers, translational scientists, and regulatory experts needing to converge earlier in development cycles. As a result, organizations that prioritize integrated device-therapy development, robust human factors engineering, and clear regulatory engagement pathways are better positioned to advance clinical adoption and scale treatment delivery.

A comprehensive exploration of the major transformative trends in device technology, decentralized care, and regulatory convergence redefining therapeutic delivery

The landscape for cell and gene therapy delivery devices is undergoing transformative shifts driven by parallel advances in therapy complexity, patient-centric care models, and digital health integration. Therapy developers increasingly prioritize minimally invasive delivery and outpatient administration, prompting device makers to innovate with autoinjectors, needle-free injectors, microfluidic systems, and wearable infusion platforms that reduce clinic dependency. At the same time, the trend toward decentralized care has accelerated investment in devices that are intuitive for home use while maintaining chain-of-custody and environmental controls for sensitive biologics.

Concurrently, manufacturing and supply chain sophistication are rising to meet the demands of personalized and batch-limited therapies. Microfluidic devices and modular infusion systems are being explored to enable localized processing and point-of-care manipulation of cell products, which could shorten critical timelines between harvest, manipulation, and delivery. Regulatory authorities are adapting guidance to address combination products and the intersection of device and biologic review, which is prompting more proactive engagement between sponsors and regulators. Moreover, digital connectivity and remote monitoring capabilities are being embedded into devices to provide real-time adherence and safety data, supporting iterative improvements in therapy protocols and post-market surveillance. Taken together, these shifts create both opportunities and complexities, and organizations must adopt integrated development pathways and robust stakeholder collaboration to capitalize on the evolving environment.

A strategic assessment of how cumulative tariff measures through 2025 are reshaping procurement, sourcing, and manufacturing resilience for delivery systems

The introduction of new tariff measures affecting imported medical components and finished devices is exerting measurable pressure on the supply chains that underpin cell and gene therapy delivery systems. Cumulative tariff actions enacted through 2025 have increased costs for certain upstream raw materials, specialized polymers, and precision components used in autoinjectors, infusion pumps, and single-use disposables. As a consequence, procurement teams are recalibrating supplier portfolios, exploring alternative sources, and reassessing total landed cost models to maintain program viability and pricing transparency.

In response, many manufacturers have initiated dual strategies of supplier diversification and nearshoring where feasible, seeking to minimize exposure to tariff volatility and reduce lead times for critical components. These approaches lead to trade-offs: relocating production can reduce tariff risk but may require capital investment, workforce training, and new quality system validations. Additionally, tariff-driven cost increases have implications for contract manufacturing negotiations and long-term supply agreements, elevating the importance of clear commercial terms, risk-sharing structures, and contingency planning.

Regulatory compliance and traceability requirements further complicate mitigation efforts, as sourcing alterations necessitate revalidation and potential device submission updates. Therefore, organizations must adopt scenario-based procurement planning that integrates tariff sensitivity, supplier qualification timelines, and regulatory impact assessments to preserve continuity of supply and maintain treatment accessibility.

A detailed set of segmentation insights linking device types, end users, product formats, therapy modalities, and distribution pathways to strategic product decisions

A nuanced understanding of segmentation dynamics is essential for aligning product development and commercialization strategies with clinical and operational realities. When studied by device type, the competitive landscape spans autoinjectors, implantable pumps, infusion pumps, microfluidic devices, needle-free injectors, pre-filled syringes, and conventional syringes, each offering distinct trade-offs between precision dosing, portability, and regulatory complexity. Likewise, analysis by end user highlights divergent needs across clinics, homecare settings, hospitals, and specialty centers; hospitals demand integrated device ecosystems and high-throughput reliability, while homecare and specialty centers prioritize ease of use, compact form factors, and remote monitoring capabilities.

Product type segmentation emphasizes the contrast between reusable systems that support lifecycle servicing and single-use disposables that simplify sterility and reduce cross-contamination risk, informing choices around maintenance infrastructure and unit economics. Therapy type segmentation divides the space into cell therapy and gene therapy; within cell therapy, CAR-T therapies, dendritic cell approaches, and stem cell treatments each impose unique handling, administration route, and timing constraints, whereas gene therapy pathways differentiate non-viral vector and viral vector strategies with implications for containment, dosing accuracy, and regulatory dossier composition. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy, with online pharmacy further split into mail order and traditional online models and retail pharmacy further differentiated between chain and independent outlets, underscore how logistics, cold chain requirements, and point-of-care coordination vary by pathway. Integrating these segmentation perspectives enables targeted product roadmaps and distribution strategies that reflect real-world use cases and stakeholder preferences.

A pragmatic examination of how regional regulatory environments, infrastructure maturity, and healthcare delivery models influence device deployment and adoption

Regional dynamics exert a profound influence on device strategy, regulatory engagement, and commercialization execution, and effective planning requires a regionally differentiated approach. In the Americas, clinical trial activity, concentrated centers of excellence, and a progressive reimbursement environment support rapid adoption of novel delivery solutions, while reimbursement pathway clarity and payer engagement remain critical for broader uptake. Europe, the Middle East & Africa present a heterogeneous regulatory landscape, where varying national device frameworks and divergent procurement models necessitate adaptive regulatory strategies and localized value propositions; this region also offers strong opportunities for centralized procurement and collaborations with public health systems in certain jurisdictions. Asia-Pacific combines rapid innovation hubs, expanding hospital infrastructure, and an increasing focus on decentralized care models, but stakeholders must navigate diverse regulatory timelines and logistics challenges across markets.

Across regions, cold chain infrastructure maturity, healthcare workforce capacity, and patient access models shape the practical viability of complex biologic administrations outside specialized centers. Therefore, companies must prioritize region-specific evidence generation, tailored training programs for clinicians and caregivers, and distribution partnerships that align with local pharmacy and hospital procurement practices. Coordinated regional strategies that balance global standards with local adaptability will be essential to scale advanced therapies while ensuring consistent quality and patient safety.

An incisive look at how manufacturers, innovators, and service providers are aligning operations and partnerships to accelerate device-enabled therapy adoption

Key corporate behaviors are converging around several strategic imperatives that influence competitive positioning in the delivery device segment. Established medtech firms are leveraging deep regulatory experience, manufacturing scale, and distribution networks to expand into specialty delivery systems, frequently pursuing partnerships or licensing arrangements with therapy developers to create integrated combination products. At the same time, agile startups and device innovators are differentiating through platform technologies-such as modular infusion architectures, compact microfluidic processors, and sensor-enabled autoinjectors-that address specific clinical pain points and enable faster iteration of human factors and connectivity features.

Contract development and manufacturing organizations play an increasingly central role, offering clean-room capacity, scalable assembly, and sterilization services that are essential for single-use disposables and complex combination products. Meanwhile, companies specializing in cold chain logistics and validated transport systems are becoming strategic partners for therapy sponsors seeking predictable delivery windows and traceability for temperature-sensitive biologics. Across the ecosystem, successful players adopt collaborative go-to-market strategies, invest in early regulatory dialogue, and prioritize rigorous human factors studies to de-risk adoption. Competitive differentiation increasingly hinges on the ability to demonstrate real-world reliability, interoperability with clinical workflows, and post-market data collection capabilities that support ongoing safety and performance monitoring.

A practical and prioritized set of strategic recommendations for device developers and therapy sponsors to align innovation, supply resilience, and regulatory readiness

Industry leaders should pursue an integrated approach that aligns device innovation with clinical workflow, regulatory strategy, and commercial execution to capture the full therapeutic and operational value of advanced biologics. First, embed human factors and clinician engagement early in the design process to ensure devices meet practical constraints of administration environments, whether in a hospital, specialty center, clinic, or the home. This early alignment reduces rework and accelerates regulatory acceptance. Second, cultivate diversified supply chains with qualified secondary suppliers and nearshoring options for critical components to mitigate tariff exposure and lead-time risk while maintaining robust quality governance.

Third, establish cross-functional teams that include regulatory, translational, manufacturing, and commercial stakeholders to navigate combination product pathways and to plan for post-market surveillance and real-world evidence collection. Fourth, invest in digital enablement-connectivity, remote monitoring, and analytics-to enhance adherence, detect early safety signals, and provide evidence of value to payers and providers. Finally, develop flexible distribution strategies that reflect differences across hospital pharmacies, online and mail order models, chain and independent retail networks, and outpatient care settings. By implementing these actions, organizations can reduce commercialization friction, support patient-centric care models, and build resilient operations that accommodate evolving therapy paradigms.

A transparent mixed-methods research approach combining primary expert engagements and secondary evidence synthesis to ensure rigorous and actionable insights

This research employs a mixed-methods approach that synthesizes qualitative expert insight with rigorous secondary validation to produce actionable findings. Primary inputs include in-depth interviews with device engineers, clinical investigators, pharmacy directors, and supply chain executives, combined with structured consultations with regulatory specialists to understand submission and post-market requirements. These stakeholder engagements are designed to capture experiential nuances around device usability, containment needs for viral and non-viral vectors, and real-world workflow constraints across hospitals, clinics, specialty centers, and homecare environments.

Secondary analysis draws on publicly available regulatory guidance, peer-reviewed literature, clinical trial registries, and supplier technical datasheets to ground findings in verifiable evidence. The research also integrates case study reviews of representative device-therapy pairings to illustrate design choices, human factors iterations, and logistics solutions. Data triangulation ensures conclusions are corroborated across multiple sources, and methodological transparency is maintained through documented assumptions, interview guides, and validation checkpoints. Throughout, the approach emphasizes reproducibility and stakeholder validation to ensure that insights reflect operational realities and inform practical decision-making across development, regulatory, and commercial functions.

A concise conclusion synthesizing how device innovation, operational resilience, and stakeholder collaboration determine successful therapy delivery outcomes

The cumulative narrative is clear: successful deployment of cell and gene therapies depends as much on delivery system design and logistical orchestration as it does on the biological modality itself. Innovations in device technology, coupled with digital connectivity and adaptive distribution models, are enabling broader decentralization of complex therapies while elevating requirements for human factors, cold chain management, and regulatory coordination. At the same time, external forces such as tariff policy shifts and regional infrastructure disparities necessitate proactive supply chain strategies and localized commercialization approaches.

Organizations that integrate cross-functional teams early, prioritize iterative user-centered design, and engage regulators proactively will reduce technical and commercial risk. Moreover, the effective pairing of device and therapy demands collaboration across a growing ecosystem of manufacturers, contract partners, logistics specialists, and healthcare providers. Ultimately, the path to scalable, safe, and patient-centric delivery of advanced biologics will be determined by the ability of stakeholders to harmonize engineering excellence, operational resilience, and evidence generation throughout the product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Drug Delivery Devices Market, by Product Type

  • 8.1. Reusable
  • 8.2. Single Use

9. Cell & Gene Therapy Drug Delivery Devices Market, by Device Type

  • 9.1. Autoinjector
  • 9.2. Implantable Pump
  • 9.3. Infusion Pump
  • 9.4. Microfluidic Device
  • 9.5. Needle-Free Injector
  • 9.6. Pre-Filled Syringe
  • 9.7. Syringe

10. Cell & Gene Therapy Drug Delivery Devices Market, by Therapy Type

  • 10.1. Cell Therapy
    • 10.1.1. CAR-T Therapy
    • 10.1.2. Dendritic Cell Therapy
    • 10.1.3. Stem Cell Therapy
  • 10.2. Gene Therapy
    • 10.2.1. Non-Viral Vector
    • 10.2.2. Viral Vector

11. Cell & Gene Therapy Drug Delivery Devices Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
    • 11.2.1. Mail Order Pharmacy
    • 11.2.2. Traditional Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Cell & Gene Therapy Drug Delivery Devices Market, by End User

  • 12.1. Clinic
  • 12.2. Homecare
  • 12.3. Hospital
  • 12.4. Specialty Center

13. Cell & Gene Therapy Drug Delivery Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Drug Delivery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Drug Delivery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Drug Delivery Devices Market

17. China Cell & Gene Therapy Drug Delivery Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Bausch & Lomb Incorporated
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bluebird bio, Inc.
  • 18.10. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • 18.11. Catalent, Inc.
  • 18.12. Dendreon Pharmaceuticals LLC.
  • 18.13. Fresenius SE & Co. KGaA
  • 18.14. Gerresheimer AG
  • 18.15. Helixmith Co., Ltd.
  • 18.16. ICU Medical, Inc.
  • 18.17. Kite Pharma, Inc. by Gilead
  • 18.18. Kolon TissueGene, Inc.
  • 18.19. MaxCyte, Inc.
  • 18.20. Novartis AG
  • 18.21. Orchard Therapeutics
  • 18.22. Pfizer, Inc.
  • 18.23. Renova Therapeutics
  • 18.24. Spark Therapeutics, Inc.
  • 18.25. Terumo Corporation
  • 18.26. uniQure N.V.
  • 18.27. Vericel Corporation
  • 18.28. West Pharmaceutical Services, Inc.
  • 18.29. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)